IFP Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,562
Closed 4680
2021
Q4
$0 Hold
1,562
﹤0.01% 3579
2021
Q3
$0 Hold
1,562
﹤0.01% 3540
2021
Q2
$0 Buy
1,562
+1,494
+2,197% ﹤0.01% 3371
2021
Q1
$0 Hold
68
﹤0.01% 3362
2020
Q4
$0 Sell
68
-48
-41% -$117 ﹤0.01% 3239
2020
Q3
$0 Buy
+116
New +$371 ﹤0.01% 3132
2017
Q4
Sell
-555
Closed -$2K 4399
2017
Q3
$2K Hold
555
﹤0.01% 3855
2017
Q2
$1K Hold
555
﹤0.01% 4044
2017
Q1
$1K Hold
555
﹤0.01% 3949
2016
Q4
$1K Hold
555
﹤0.01% 3940
2016
Q3
$2K Sell
555
-1,026
-65% -$3.26K ﹤0.01% 3679
2016
Q2
$5K Buy
+1,581
New +$5.27K ﹤0.01% 3211
2016
Q1
Sell
-1,551
Closed -$5K 4401
2015
Q4
$5K Buy
+1,551
New +$6.49K ﹤0.01% 3031

Other funds holding PDLI

IFP Advisors's PDLI Position: Q1 2022 in Review

IFP Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2022, closing a stake of 1,562 shares.

IFP Advisors first reported a position in PDLI in Q4 2015 and held it in 13 quarters. The position peaked at $5K in Q2 2016. 5 funds tracked by Wall St. Rank hold PDLI as of Q1 2022.

  • IFP Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2022 after selling out during the quarter.
  • IFP Advisors sold 1,562 PDL BioPharma, Inc. shares in Q1 2022.
  • IFP Advisors first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 13 quarters.
  • IFP Advisors's PDL BioPharma, Inc. position peaked at $5K in Q2 2016.
  • 5 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2022.

Based on IFP Advisors's 13F filing for Q1 2022, filed 8 Aug 2022.